LONDON , Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX ) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience. "ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe ," said James Foster , CEO of Virax Biolabs.
"We believe this partnership will meaningfully expand our commercial footprint in the UK and Ireland and make ImmuneSelect accessible to researchers and pharmaceutical companies as they work to better understand the role of T cell response and immune status." "We are happy to partner with innovative companies like Virax Biolabs," commented Martijn Blommaart, Director of Supplier Development at Europa Biosite. "We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the UK & Ireland " About ImmuneSelect ImmuneSelect is the Company's portfolio of research products dedicated to investigating adaptive immunity.
Products within the ImmuneSelect brand are for research and investigation.
